You are here: Industry Insights > Roche

News List

Lead Pharma enters oral molecules development deal with Roche pharmaceutical-technology
November 18, 2020
Lead Pharma has signed a collaboration and licence agreement with Roche for the development of oral small molecules to treat a broad range of immune-mediated diseases.
Lead Pharma and Roche Enter Collaboration & License Agreement contractpharma
November 17, 2020
Lead Pharma, a clinical stage pharmaceutical company, has entered into a collaboration and license agreement with Roche to develop oral small molecules to treat a broad range of immune mediated diseases.
CEVEC, Roche Ink ELEVECTA Technology License Agreement contractpharma
November 12, 2020
CEVEC Pharmaceuticals GmbH (CEVEC) signed an option and license agreement with Roche for the use of its newly launched ELEVECTA Technology for large scale manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications.
Roche obtains EC approval for Tecentriq/Avastin to treat liver cancer pharmaceutical-technology
November 05, 2020
Roche has obtained approval from the European Commission for Tecentriq (atezolizumab) and Avastin (bevacizumab) combination to treat adult patients with advanced or unresectable hepatocellular carcinoma (HCC).
Oncolytics Biotech, Roche, AIO Initiate Gastrointestinal Cancer Trial americanpharmaceuticalreview
November 05, 2020
Oncolytics Biotech® announced a new multi-indication gastrointestinal (GI) cancer study to be managed by AIO. The phase 1/2 trial, known as GOBLET, will investigate the use of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor ...
Roche, Atea Pharma to Develop Potential Oral COVID-19 Treatment contractpharma
October 23, 2020
Roche and Atea Pharmaceuticals, Inc. have partnered to develop, manufacture and distribute AT-527, Atea’s investigational oral direct-acting antiviral, to treat COVID-19.
Roche Canada to Invest $500M to Create 500 Jobs in Ontario contractpharma
October 22, 2020
Hoffmann-La Roche Limited (Roche Canada) has unveiled a major jobs investment into Ontario's life sciences industry that will bring up to 500 highly skilled and specialized full-time positions to the City of Mississauga.
Roche signs deal with Dyno Therapeutics for gene therapy vectors pharmatimes
October 16, 2020
Roche has signed a collaborative agreement with Dyno Therapeutics for the development of adeno-associated virus (AAV) vectors for gene therapies for central nervous system (CNS) disease and liver-directed therapies.
Dyno, Roche Ink Gene Therapy Deal Worth up to $1.8B contractpharma
October 16, 2020
Collaboration combines Dyno’s AI-powered AAV vector capabilities with Roche and Spark Therapeutics’ gene therapy capabilities.
Roche acquires Enterprise Therapeutics’ potentiator portfolio pharmaceutical-technology
October 10, 2020
Roche Group has acquired biopharma firm Enterprise Therapeutics’ TMEM16A potentiator portfolio, developed by its member Genentech.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page